Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bionet TherapeuticsROCO:7808 +2.50%20 EV-to-EBIT is -17.10 as of Sep. 08, 2026. GuruFocus rates ROCO:7808 with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 365 Biotechnology companies, Bionet Therapeutics ranks worse than 273972.33% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Bionet Therapeutics's Enterprise Value for the quarter that ended in Jun. 2026 was NT$1,508.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bionet Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-83.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionet Therapeutics EV-to-EBIT Related Terms
Bionet Therapeutics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Bionet Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7808 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Bionet Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionet Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bionet Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Bionet Therapeutics's EV-to-EBIT falls into.
Bionet Therapeutics's current Enterprise Value is NT$1,431.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bionet Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-83.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionet Therapeutics (ROCO:7808) has a EV-to-EBIT of -17.10 as of Sep. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bionet Therapeutics and its competitors. According to the industry distribution chart, Bionet Therapeutics ranks #999999 out of 365 companies in the Biotechnology industry.
Is Bionet Therapeutics' EV-to-EBIT too high?
Bionet Therapeutics' current EV-to-EBIT is -17.10. Based on the distribution chart, Bionet Therapeutics ranks #999999 out of 365 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Bionet Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Bionet Therapeutics' EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bionet Therapeutics ranks #999999 out of 365 companies for EV-to-EBIT. This places Bionet Therapeutics in the lower half of its industry. The industry median EV-to-EBIT is 15.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.65, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bionet Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionet Therapeutics's current EV-to-EBIT is -17.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionet Therapeutics stock overvalued right now?
Bionet Therapeutics (ROCO:7808) has a current EV-to-EBIT of -17.10. The current EV-to-EBIT is -17.10. Bionet Therapeutics' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Bionet Therapeutics (ROCO:7808), the current EV-to-EBIT is -17.10 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bionet Therapeutics Corp is a patient-focused on regenerative medicinal products, R&D, exosomes, and gene/cell therapy biopharmaceutical company. The group develops, manufactures, and provides regenerative medicine preparations and cellular therapies to meet the evolving health needs of people at different stages of life. It focused on treatments that improve patient outcomes. It provides Cell Therapy Products and CRDMO Services.
20GF Score
Get the complete analysis for ROCO:7808
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7808 has been successfully added to your 
